PDF(Pubmed)
Abstract：
Transdermal microneedles have demonstrated promising potential as an alternative to typical drug administration routes for the treatment of various diseases. As microneedles offer lower administration burden with enhanced patient adherence and reduced ecological footprint, there is a need for further exploitation of microneedle devices. One of the main objectives of this work was to initially develop an innovative biobased photocurable resin with high biobased carbon content comprising isobornyl acrylate (IBA) and pentaerythritol tetraacrylate blends (50:50 wt/wt). The optimization of the printing and curing process resulted in μNe3dle arrays with durable mechanical properties and piercing capacity. Another objective of the work was to employ the 3D printed hollow μNe3dles for the treatment of osteoporosis in vivo. The 3D printed μNe3dle arrays were used to administer denosumab (Dmab), a monoclonal antibody, to osteoporotic mice, and the serum concentrations of critical bone minerals were monitored for six months to assess recovery. It was found that the Dmab administered by the 3D printed μNe3dles showed fast in vitro rates and induced an enhanced therapeutic effect in restoring bone-related minerals compared to subcutaneous injections. The findings of this study introduce a novel green approach with a low ecological footprint for 3D printing of biobased μNe3dles, which can be tailored to improve clinical outcomes and patient compliance for chronic diseases.
摘要：
经皮微针已显示出作为用于治疗各种疾病的典型药物施用途径的替代方案的有希望的潜力。由于微针提供了较低的给药负担，增强了患者的依从性和减少了生态足迹，需要进一步开发微针装置。这项工作的主要目标之一是最初开发一种具有高生物基碳含量的创新生物基可光固化树脂，包括丙烯酸异冰片酯（IBA）和季戊四醇四丙烯酸酯共混物（50：50wt/wt）。印刷和固化过程的优化导致μNe3dle阵列具有持久的机械性能和刺穿能力。这项工作的另一个目的是使用3D打印的空心μNe3dles在体内治疗骨质疏松症。3D打印的μNe3dle阵列用于管理denosumab（Dmab），单克隆抗体，对骨质疏松小鼠来说，并监测血清中关键骨矿物质浓度6个月以评估恢复情况。发现与皮下注射相比，由3D打印的μNe3dles施用的Dmab显示出快速的体外速率，并在恢复骨相关矿物质方面诱导了增强的治疗效果。这项研究的发现为生物基μNe3dles的3D打印引入了一种低生态足迹的新型绿色方法，可以对其进行定制，以改善慢性病的临床结果和患者依从性。
